Stock Price Quote

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE665.65-36 (-5.13 %)
PREV CLOSE ( ) 701.65
OPEN PRICE ( ) 699.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 67295
TODAY'S LOW / HIGH ( )658.90 699.65
52 WK LOW / HIGH ( )299.3 724
NSE665.00-35.7 (-5.09 %)
PREV CLOSE( ) 700.70
OPEN PRICE ( ) 700.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 665.00 (319)
VOLUME 1015524
TODAY'S LOW / HIGH( ) 655.00 700.60
52 WK LOW / HIGH ( )299.05 724.4
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-06 1978
Management Info
Shyam S Bhartia - Chairman Priyavrat Bhartia - Managing Director
Registered Office

Address Bhartiagram ,Jyotiba Phoolay Nagar, ,
Gajraula,
Uttar Pradesh-244223

Phone 05924-267437

Email invstors@jubl.com

Website www.jubilantpharmova.com

Registrars Details
Alankit Assignments Ltd.
205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi
Listing : BSE, NSE, MCX

NEWS

18Apr Jubilant Pharmova informs about closur
Jubilant Pharmova has informed that the Company’s subsidiary Jubilant Ca..
30Mar Jubilant Pharmova informs about update
Jubilant Pharmova has informed that in continuation to earlier letter da..
26Mar Jubilant Pharmova informs about change
Pursuant to Regulation 30 of the SEBI Listing Regulations, Jubilant Phar..
11Mar Jubilant Pharmova informs about analys
In reference to its disclosure dated March 05, 2024 wherein the company..
17Feb Jubilant Pharmova informs about updates
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-24498.8
Gross Profit -23 793.4
Operating Profit 1831411.1
Net Sales 17528101.2

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

PROMOTERS 50.68%
NON-INSTITUTION 26.49%
MUTUAL FUNDS/UTI 2.27%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Jubilant Pharmova Ltd.

Jubilant Pharmova Ltd. was incorporated in the year 1978. Its today's share price is 665.65. Its current market capitalisation stands at Rs 10602.55 Cr. In the latest quarter, company has reported Gross Sales of Rs. 8101.17 Cr and Total Income of Rs.9480.09 Cr. The company's management includes Naresh Kapoor, Shirish G Belapure, Arun Seth, Vivek Mehra, Sushil Kumar Roongta, Ashok Misra, Sudha Pillai, S Sridhar, Arvind Chokhany, Arjun Shanker Bhartia, Priyavrat Bhartia, Hari S Bhartia, Shyam S Bhartia.

It is listed on the BSE with a BSE Code of 530019 , NSE with an NSE Symbol of JUBLPHARMA and ISIN of INE700A01033. It's Registered office is at Bhartiagram ,Jyotiba Phoolay Nagar, Gajraula-244223, Uttar Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, KN Gutgutia & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.